We are live on ! Find out more

CLLS

Cellectis

CLLS

Market cap $358M

3.56 USD

+0.14

4.09%

At close Updated Aug 27, 4:00 PM EDT

1 day

4.09%

5 days

6.91%

1 month

23.18%

3 months

-1.93%

6 months

-8.25%

Year to date

-25.83%

1 year

33.33%

5 years

-75.05%

10 years

-86.55%

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 229

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Cellectis Reports Financial Results for the Second Quarter 2026

Cellectis Reports Financial Results for the Second Quarter 2026

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)

Monthly information on share capital and company voting rights

Cellectis to Report Second Quarter Financial Results on August 6, 2026

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second quarter 2026 ending June 30, 2026 on Thursday, August 6, 2026 after the close of the US market.

Cellectis to Report Second Quarter Financial Results on August 6, 2026

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced two additions to its executive leadership team: Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer.

Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preliminary data from the NATHALI-01 study evaluating eti-cel, a dual CD20 and CD22 directed CAR-T in relapsed/refractory B-cell non Hodgkin lymphoma (r/r B-NHL), at the European Hematology Association (EHA) 2026 Annual Congress.

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Monthly information on share capital and company voting rights

PARIS, June 03, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital Total number of voting rights 05/31/2026 100,691,658 106,134,467 For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com  Attachments Voting_Rights_PR_May_2026_EN

Monthly information on share capital and company voting rights

Cellectis' Annual Shareholders General Meeting to be Held on June 25, 2026

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 25, 2026 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Cellectis' Annual Shareholders General Meeting to be Held on June 25, 2026

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced upcoming presentations on the BALLI-01 and NATHALI-01 clinical trials, at the European Hematology Association (EHA) annual congress, on June 11-14, 2026, in Stockholm, Sweden.

Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

See News Rankings

Price charts implemented using Lightweight Charts™